Total revenues in Q1 2024 increased to $37 million compared to$16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by$40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for bottom line ...